The real-life outcome of pazopanib in patients with advanced soft tissue sarcoma: A retrospective cross-sectional study of a Turkish cohort

Basit Öğe Kaydı
dc.contributor.authorKaraagac, Mustafa
dc.contributor.authorSezgin, Yasin
dc.contributor.authorEryilmaz, Melek Karakurt
dc.contributor.authorAraz, Murat
dc.contributor.authorKaplan, Muhammet Ali
dc.contributor.authorArtac, Mehmet
dc.date.accessioned2024-04-24T17:14:40Z
dc.date.available2024-04-24T17:14:40Z
dc.date.issued2020
dc.departmentDicle Üniversitesien_US
dc.description.abstractIntroduction Soft tissue sarcomas are a heterogeneous and rare group of cancers with a short median overall survival despite the chemotherapy. Pazopanib has approval for the treatment of advanced soft tissue sarcoma. We aimed to investigate the clinical outcomes of Turkish patients with advanced soft tissue sarcoma who received pazopanib. Patients and methods This was a retrospective study. The inclusion criteria were: >= 18 years of age, having histologically proven advanced soft tissue sarcoma and receiving pazopanib at least one day. Results A total of 79 patients were assessed in this study. The median age was 49.6 years. The average dose intensity of pazopanib was 767 mg (400-800). The median duration of pazopanib treatment was 6.11 months. Fourteen patients (17.7%) used pazopanib at first line for advanced soft tissue sarcomas. The most common cause of discontinuation of pazopanib was the progression of the disease (89.6%). Pazopanib was well tolerated. The most common grade >= 3 side effect was anemia. The most common grade <= 2 side effects were anemia and hyperbilirubinemia. The median progression-free survival, overall survival, and follow-up were 3.97months, 11.40months, and 32.72 months, respectively. Female gender, good performance status, and the presence of pazopanib-induced hypothyroidism were associated with longer progression-free survival. Also, good performance status and being a responder to first-line treatment were associated with longer overall survival. Conclusions We showed that pazopanib was well tolerated and had clinical benefit in patients with advanced soft tissue sarcoma in a Turkish cohort. This is the first study that suggests pazopanib-induced hypothyroidism may act as a predictive marker for better outcomes in patients with advanced soft tissue sarcoma.en_US
dc.identifier.doi10.1177/1078155220904138
dc.identifier.endpage1666en_US
dc.identifier.issn1078-1552
dc.identifier.issn1477-092X
dc.identifier.issue7en_US
dc.identifier.pmid32063110
dc.identifier.scopus2-s2.0-85081549576
dc.identifier.scopusqualityQ3
dc.identifier.startpage1657en_US
dc.identifier.urihttps://doi.org/10.1177/1078155220904138
dc.identifier.urihttps://hdl.handle.net/11468/18129
dc.identifier.volume26en_US
dc.identifier.wosWOS:000514044200001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofJournal of Oncology Pharmacy Practice
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHypothyroidismen_US
dc.subjectPazopaniben_US
dc.subjectPredictiveen_US
dc.subjectSarcomaen_US
dc.subjectSurvivalen_US
dc.titleThe real-life outcome of pazopanib in patients with advanced soft tissue sarcoma: A retrospective cross-sectional study of a Turkish cohorten_US
dc.titleThe real-life outcome of pazopanib in patients with advanced soft tissue sarcoma: A retrospective cross-sectional study of a Turkish cohort
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu